| 1 |
Gan J, Liu S, Chen Z, Yang Y, Ma L, Meng Q, Wang XD, Liu C, Li X, Zhang W, Ji Y. Elevated Plasma Orexin-A Levels in Prodromal Dementia with Lewy Bodies. J Alzheimers Dis 2022;1:1-12. [PMID: 35723094 DOI: 10.3233/JAD-220082] [Reference Citation Analysis]
|
| 2 |
Oliveira LM, Henrique E, Bustelli IB, Netto NF, Moreira TS, Takakura AC, Caetano AL. Depletion of hypothalamic hypocretin/orexin neurons correlates with impaired memory in a Parkinson's disease animal model. Experimental Neurology 2020;323:113110. [DOI: 10.1016/j.expneurol.2019.113110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 3 |
Bian K, Liu C, Wang Y, Xue Y, Chen L. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice. Neurosci Lett 2021;765:136291. [PMID: 34666119 DOI: 10.1016/j.neulet.2021.136291] [Reference Citation Analysis]
|
| 4 |
Liu C, Xue Y, Liu MF, Wang Y, Chen L. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Neurochem Int 2020;138:104754. [PMID: 32422324 DOI: 10.1016/j.neuint.2020.104754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Torres ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C, Baldauf L, Fleming S, Masliah E, Chesselet MF, Fanselow MS, Richter F. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. Neurobiol Dis 2021;158:105478. [PMID: 34390837 DOI: 10.1016/j.nbd.2021.105478] [Reference Citation Analysis]
|
| 6 |
Faesel N, Kolodziejczyk MH, Koch M, Fendt M. Orexin deficiency affects sociability and the acquisition, expression, and extinction of conditioned social fear. Brain Res 2021;1751:147199. [PMID: 33160959 DOI: 10.1016/j.brainres.2020.147199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Stanojlovic M, Pallais JP, Kotz CM. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. Int J Mol Sci 2021;22:E795. [PMID: 33466831 DOI: 10.3390/ijms22020795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Torre-Muruzabal T, Devoght J, Van den Haute C, Brône B, Van der Perren A, Baekelandt V. Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an α-synuclein based rat model for Parkinson's disease. Acta Neuropathol Commun 2019;7:160. [PMID: 31640762 DOI: 10.1186/s40478-019-0814-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 9 |
Hussein A, Guevara CA, Del Valle P, Gupta S, Benson DL, Huntley GW. Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction. Neuroscientist 2021;:10738584211011979. [PMID: 33966533 DOI: 10.1177/10738584211011979] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Ji MH, Lei L, Gao DP, Tong JH, Wang Y, Yang JJ. Neural network disturbance in the medial prefrontal cortex might contribute to cognitive impairments induced by neuroinflammation. Brain Behav Immun 2020;89:133-44. [PMID: 32505714 DOI: 10.1016/j.bbi.2020.06.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
